Skip to main content
SpringerLink
Log in

The application of extreme value theory to pharmacometrics

  • Original Paper
  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

This article has been updated

Abstract

Clinical trials are often analyzed by examining the means, e.g., what is the mean treatment effect or what is the mean treatment difference, but there are times when analysis of the maximums (or minimums) are of interest. For instance, what is the highest heart rate that could be observed or what the smallest treatment effect that could be expected? While inference on the means is based on the central limit theorem, the corresponding theorem for maximums or minimums is the Fisher–Tippett theorem, also called the extreme value theorem (EVT). This manuscript will introduce EVT to pharmacometricians, particularly block maxima analysis and peak over threshold analysis, and provide examples for how it can be applied to pharmacometric data, particularly the analysis of pharmacokinetics and ECG safety data, like QTcF intervals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12

Similar content being viewed by others

Change history

  • 09 July 2021

    The original online version of this article was revised: Supplementary file was missing from this article and has now been uploaded.

References

  1. Gumbel EJ (1958) Statistics of extremes. Dover Publications, Mineola

    Book  Google Scholar 

  2. O'Connor T (2018) Fukushima nuclear plant: tsunami wall could have avoided disaster but boss scrapped the plan, employee testifies. Accessed 14 April 2019 from https://www.newsweek.com/fukushima-nuclear-plant-owners-face-trail-one-worlds-most-radioactive-886025

  3. Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M, Tilson HH, Joseph M, Dai WS, Chen D et al (1991) A population-based study of Stevens–Johnson syndrome. Incidence and antecedent drug exposures. Arch Dermatol 127:831–838

    Article  CAS  Google Scholar 

  4. Bohigian GM (2015) The history of Stevens–Johnson Syndrome and a case study. https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?article=1000&context=historyofmedicine_presentations

  5. Beirlant J, Goegebeur Y, Segers J, Teugels J (2004) Statistics of extremes: theory and applications. Wiley, New York

    Book  Google Scholar 

  6. Southworth H, Heffernan JE (2012) Multivariate extreme value modelling of laboratory safety data from clinical studies. Pharm Stat 11:367–372

    Article  Google Scholar 

  7. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL (2002) Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Intl J Antimicrob Drugs 19:355–358

    Article  CAS  Google Scholar 

  8. Olmo J (2009) Extreme value theory filtering techniques for outlier detection

  9. Benetazzo A, Ardhuin F, Bergamasco F, Cavaleri L, Veras Guimaraes P, Schwendeman M, Sclavo M, Thomson J, Torsello A (2017) On the shape and likelihood of oceanic rogue waves. Sci. Rep 7:Article 8276

  10. Knopoff L, Kagan G (1977) Analysis of the theory of extremes as applied to earthquake problems. J Geophys Res 82:5647–5657

    Article  Google Scholar 

  11. Henry JB III, Hsieh P-H (2010) Extreme value analysis for partitioned insurance losses. Variance 3:214–238

    Google Scholar 

  12. Louangrath P (2016) Stock price analysis under extreme value theory. Posted 14 Jan 2016.

  13. Holmes TP, Huggett RJ Jr, Westerling AL (2008) Statistical analysis of large wildfires. In: Holmes TP, Prestemon JP, Abt KL (eds) The economics of forest disturbances: wildfires, storms, and invasive species. Springer, New York, pp 59–77

    Chapter  Google Scholar 

  14. Minkah R (2016) An application of extreme value theory to the management of a hydroelectric dam. SpringerPlus. 5:Article 96

  15. Einmahl JHJ, Smeets SGWR (2011) Ultimate 100 m world records through extreme value theory. Stat Neerl 65:32–42

    Article  Google Scholar 

  16. Southworth H, Heffernan JE (2012) Extreme value modelling of laboratory safety data from clinical studies. Pharm Stat 11:367

    Article  Google Scholar 

  17. Southworth H (2014) Predicting potential liver toxicity from phase 2 data: a case study with ximelagatran. Stat Med 33:2914–2923

    Article  Google Scholar 

  18. Bonate PL (2011) Pharmacokinetic: pharmacodynamic modeling and simulation. Springer, New York

    Book  Google Scholar 

  19. Kodra E, Ganguly AR (2014) Asymmetry of projected increases in extreme temperature distributions. Sci Rep 4:5884

    Article  Google Scholar 

  20. Coles S (2001) An introductioin to statistical modeling of extreme values. Springer, London

    Book  Google Scholar 

  21. Malik M, van Gelderen M, Lee JH, Kowalski DL, Yen M, Goldwater R, Mujais SK, Schaddelee M, de Koning P, Kaibara A, Moy SS, Keirns JJ (2012) Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Therap 92:696–706

    Article  CAS  Google Scholar 

  22. Jenkinson AF (1955) The frequency distribution of the annual maximum (or minimum) of meteorological element. Q J R Meteorl Socs 81:158–171

    Article  Google Scholar 

  23. United States Department of Health and Human Services, Food and Drug Administration, and Center for Drug Evaluation and Research (2005) Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (E14)

  24. Taubel J, Prasad K, Rosano G, Ferber G, Wibberley H, Cole ST, van Langenhoven L, Fernandes S, Djumanov D, Sugiyama A (2020) The effects of fluoroquinolones moxifloxacin and levofloxacin on the QT subintervals: sex differences in ventricular repolarization. J Clin Pharmacol 60:400–408

    Article  Google Scholar 

  25. Florian JA, Tornoe CW, Brundage RC, Parekh A, Garnett CE (2011) Population pharmacokinetic and concentration–QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J Clin Pharmacol 51:1152–1162

    Article  CAS  Google Scholar 

  26. Gilleland E, Ribatet M, Stephenson AG (2013) A software review for extreme value analysis. Extremes 16:103–119

    Article  Google Scholar 

  27. Dutang C, Jaunatre K (2020) CRAN task view: extreme value analysis. https://cran.r-project.org/web/views/ExtremeValue.html

  28. Gilleland E, Katz RW (2016) extRemes 2.0: an extreme value analysis package in R. J Stat Softw 72:1–39

    Article  Google Scholar 

  29. Ribatet M, Dutang C (2019) Package 'POT': generalized Pareto distribution and peaks over threshold. https://cran.r-project.org/web/packages/POT/POT.pdf

Download references

Author information

Authors and Affiliations

  1. Astellas, 1 Astellas Way, Northbrook, IL, 60062, USA

    Peter L. Bonate

Authors
  1. Peter L. Bonate
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter L. Bonate.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 408 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bonate, P.L. The application of extreme value theory to pharmacometrics. J Pharmacokinet Pharmacodyn 48, 83–97 (2021). https://doi.org/10.1007/s10928-020-09721-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-020-09721-0

Keywords

Search

Navigation